Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: BW who wrote (7138)	2/22/2002 11:04:51 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48461

I mentioned JPM once here, and as I understand it, JPM has $trillions in derivatives exposure, and it is in one of those "twixt" positions, too big to let fail, too big to bail...And the Feds are starting to look at the JPM books, and I bet they are "fishy" to say the least.. On top of that, they have doa Argentine & Enron loans, and worse, possible hidden Enron induced derivative exposure. Ouch! If the media pushes this story, the market in general will become real toasty, real fast... I own some JPM Mar 30 puts.... Don't know about strollers, but some of the toydogs would be one way to play that sector... __________________________________________________________ Check out this story, 2 of our bio-rats may have a tie-in application> Device Could Lead to DNA Tests in Doctor's Office Thu Feb 21, 5:34 PM ET NEW YORK (Reuters Health) - Illinois researchers have developed a simpler, but still highly accurate, method for detecting the genetic material DNA. The technology could be used to develop hand-held DNA-screening devices that doctors could use during routine office visits, one of the investigators told Reuters Health. "We have developed a detection system for genetic and infectious diseases that is thousands of times more sensitive than state-of-the-art alternatives," said Dr. Chad A. Mirkin, of Northwestern University in Evanston. Besides accelerating genetic research, the system will "revolutionize the way people are screened and diagnosed" for potentially life-threatening diseases, according to Mirkin. "This technology lays the groundwork for a hand-held device that could be used by doctors to screen a patient for every type of possible infectious or genetic disease over the time frame of an ordinary office visit," Mirkin said. One of the obstacles to using DNA screening in the clinic is that currently available detection methods rely on testing called polymerase chain reaction (PCR) or comparable systems that are not practical to use outside of a laboratory setting. In addition, screening now requires a complicated step called thermal-stringency wash that makes DNA screening in a doctor's office impractical. In the February 22nd issue of the journal Science, Mirkin and his colleagues report the development of an accurate DNA screening method that gets around some of these obstacles. The new screening method uses an electric current, tiny gold particles called nanoparticles and strands of synthesized DNA. When a glass slide is placed in a fluid containing DNA to be screened, strands of DNA on the slide match up with corresponding DNA in the fluid. These matches are not always perfect, and normally, the complicated step of thermal-stringency wash is used to eliminate these imperfect matches. But Mirkin and his colleagues discovered that changing the concentration of a salt solution--a much easier task--can do the same thing as thermal-stringency wash. Besides making it possible for doctors to detect diseases rapidly during a routine office visit, the screening method has other possible uses. For instance, a hand-held device might be used to detect anthrax, smallpox and other biological weapons. The technology has been licensed to the Northbrook, Illinois-based company Nanosphere, which is working on developing a prototype device, according to Mirkin. The Northwestern researcher is one of the company's founders.